Page 123 - பிராங்க்ஃபர்ட் ஸ்டாக் பரிமாற்றம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
DGAP-CMS: Siemens Aktiengesellschaft: Veröffentlichung einer Kapitalmarktinformation
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
DGAP-CMS : Logwin AG: Announcement pursuant to Article 5 (1b) and (3) of Regulation (EU) No 596/2014 and Art 2 (2) and (3) of Commission Delegated Regulation (EU) No 2016/1052
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
PTA-CMS: Edel SE & Co KGaA: Bekanntmachung entsprechend Art 5 Abs 1 lit b) und Abs 3 der Verordnung (EU) Nr 596/2014 (MAR) - i V m Art 2 Abs 2 und Abs 3 der Delegierten Verordnung (EU) Nr 2016/1052
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
DGAP-CMS: Grand City Properties S A : Release of a capital market information
boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG, and Medac signed an exclusive license and supply agreement for the marketing of both Ameluz and BF-RhodoLED in Poland. The agreement has a term of 5 years commencing with the start of sales in Poland.
Under the terms of the agreement, Medac will make an immediate one-time upfront payment of EUR 50,000 to the Company, plus an additional one-time payment of EUR 150,000 following receipt of the drug’s reimbursement eligibility from the Polish health insurance providers. According to the agreement, Medac receives exclusive distribution rights for Poland. Once reimbursement eligibility has been granted in Poland, Biofrontera will supply Ameluz® to Medac at a fixed transfer price based on the expected net revenues.